Thymoma future or investigational therapies: Difference between revisions
Amr Marawan (talk | contribs) No edit summary |
Gerald Chi- (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
==Targeted Therapy== | ==Targeted Therapy== | ||
*'''KIT pathway''' | *'''KIT pathway''' | ||
It is overexpressed by immunohistochemistry in 2% of thymomas and in 79%of thymic carcinomas. Imatinib and nilotinib are been tried in several clinical trials.<ref name="www.ncbi.nlm.nih. | It is overexpressed by immunohistochemistry in 2% of thymomas and in 79%of thymic carcinomas. Imatinib and nilotinib are been tried in several clinical trials.<ref name="www.ncbi.nlm.nih.gov01">{{Cite web | last = | first = | title = Thymic carcinoma with overexpression of mutated... [N Engl J Med. 2004] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed/15201427 | publisher = | date = | accessdate = }}</ref> | ||
*'''Epidermal growth factor pathway''' | *'''Epidermal growth factor pathway''' | ||
It is overexpressed by immunohistochemistry in 70% of thymomas and in 53%of thymic carcinomas. Cetuximab, erlotinib, gefitinib are being used in diff clinical trials.<ref name="www.ncbi.nlm.nih. | It is overexpressed by immunohistochemistry in 70% of thymomas and in 53%of thymic carcinomas. Cetuximab, erlotinib, gefitinib are being used in diff clinical trials.<ref name="www.ncbi.nlm.nih.gov02">{{Cite web | last = | first = | title = Response of thymoma to cetuximab. [Lancet Oncol. 2007] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed/17466903 | publisher = | date = | accessdate = }}</ref> | ||
*'''IGF-1R pathway''' | *'''IGF-1R pathway''' | ||
Expression of IGF-1R was found in 4% of thymomas and in 37% of thymic carcinomas. Figitumumab and cixutumumab have been tried in ndifferent clinical trials.<ref name="www.ncbi.nlm.nih. | Expression of IGF-1R was found in 4% of thymomas and in 37% of thymic carcinomas. Figitumumab and cixutumumab have been tried in ndifferent clinical trials.<ref name="www.ncbi.nlm.nih.gov03">{{Cite web | last = | first = | title = Thymic Malignancies: From Clinical Management to Targeted Therapies | url = http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675690/ | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 21:45, 24 February 2014
Medi
|
Thymoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Thymoma future or investigational therapies |
|
Risk calculators and risk factors for Thymoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amr Marawan, M.D. [2]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Due to the advancement in understanding the molecular biology of the disease, there is an increased number of targeted therapies being tested in clinical trials, but the results have so far been disappointing.
Targeted Therapy
- KIT pathway
It is overexpressed by immunohistochemistry in 2% of thymomas and in 79%of thymic carcinomas. Imatinib and nilotinib are been tried in several clinical trials.[1]
- Epidermal growth factor pathway
It is overexpressed by immunohistochemistry in 70% of thymomas and in 53%of thymic carcinomas. Cetuximab, erlotinib, gefitinib are being used in diff clinical trials.[2]
- IGF-1R pathway
Expression of IGF-1R was found in 4% of thymomas and in 37% of thymic carcinomas. Figitumumab and cixutumumab have been tried in ndifferent clinical trials.[3]